ESMO 2023

Preoperative checkpointinihition in ER+ disease

DATO-DX - where is it going?

My highlights of ESMO23 in metastatic breast cancer

Remarkable efficacies in patients with HER2+ mBC with brain metastases

Highlights in eBC

5 year follow-up

Lu-PSMA leads forward

The FGFR story in bladder cancer at ESMO23

When the history of ADC is written: Redefining first-line standard of care in mUC!

Early use of enzalutamide in advanced prostate cancer

New 3rd line therapy for RCC

Clearing up non-clear cell RCC

Amivantamab as a new SoC for EGFR Exon 20 Insertion-mutated aNSCLC

Perioperativ immunotherapy for all resectable stage II-IIIb NSCLC patients

Datopotamab deruxtecan - new SOC in 2nd line adv/met NSCLC?

ALINA - immediate change of practice!

My highlights from ESMO 2023

Tarlatamab in SCLC

Data updates for CDK4/6 inhibitors in EBC at ESMO23 - implications for clinical practice

What was the most exciting news at ESMO23?

What is your definition of triple-negative breast cancer?

Anticipated updates and exciting new data for checkpointinhibitors

New and better biomarkers are needed!

5 year follow-up

Highlights in eBC

Our guidelines are correct

HR+ study with > 20 % PCR

MonarchE - trial update

Consolidation of data in early HR+ and triple-negative breast cancer

Preoperative checkpointinihition in ER+ disease

Negative EFS results from NeoTrip

Carry-over effects in monarchE confirmed

Detailed view of nodal-negative patients

Prognostic score in early HR+/HER2-BC: translational data from ADAPT

Neoadjuvant IO - is their new strategy in HR+ breast cancer

Metabolomics reveal differential expression of OMEGA 3 & OMEGA 6 in neoadjuvant treatment

Analysis of tumour microenvironment and immunophenotype in TNBC

My highlights of ESMO23 in early breast cancer

Use of immunotherapy in the perioperative setting of luminal Her2- BC

Immunoncology in eBC - triple negative and more?

Ribociclib effective in all subtypes

Clinically relevant effect of pembro also in PCR

ER-low corresponds diagnostically to ER-0 breast cancer

Pembrolizumab solidifies as SOC in early-stage TNBC

New data on neoadjuvant immunotherapy

Nouvelles données sur l'immunothérapie néoadjuvante

La Metabolomica svela l’importanza di OMEGA 3 & OMEGA 6 nel condizionare la risposta alla terapia neo-adiuvante

MonarchE - mise à jour de l'essai

Punti salienti in eBC

Studio NeoTrip: negativi i risultati

What was the most exciting news at ESMO23?

New ADC for metastatic breast cancer?

New targets, new linker, new ADCs - much more to learn with new therapies!

Improvement of therapy outcome by app-based patient education

ADCs in HER2+, HER2low and TNBC - what is the future of ADCs?

How to organize a molecular tumorboards in breast cancer?

Can surgery be spared following primary systemic therapy?

ADC + Immunotherapy - the BEGONIA study paradigm

T-DXd also effective for brain metastases

Dato-DXd - new player in advanced luminal disease

New ADC in HR+ disease

TROP2 expression as a potential mechanism of resistance in HER2+ patients

Robust data from the monarchE

Remarkable efficacies in patients with HER2+ mBC with brain metastases

Highlights in mBC

OP-1250 (Palezestrant) confirms the role of SIRDs after CDK4/6i

HER2DX in the PHERgain trial

Fulvestran better than anastrozole, but no survival benefit

T-DXd in HER2+ patients with brain metastases

Still on track for success in HER2-low MBC

DATO-DX - where is it going?

HS20089 - a novel ADC is coming for TNBC

Even more new generation ADCs in breast cancer?

My highlights of ESMO23 in metastatic breast cancer

TULIP: Trastuzumab duocarmazine without OS benefit

Our guidelines are correct

OP seems to be dispensable for super responders

T-DXd - new standard of care for brain mets?

Duvalumab + Dato-DXd effective

Abemaciclib remains consistent in 5-year follow-up

Patient-centered molecular medicine - a new approach

Benefit for SG even after intensive pretreatment

Improved oncological therapy with the smartphone

Czy możliwa jest rezygnacja z chirurgii po indukcyjnym leczeniu systemowym?

La expresión de TROP2 como potencial mecanismo de resistencia en pacientes HER2+.

ADC + Immunothérapie: L'exemple de l'étude BEGONIA par le cancer triple negative

Punti salienti in mBC

T-DXd - nowy standard postępowania w przerzutach do mózgu?

OP-1250 (Palezestrant) ulteriore conferma del ruolo dei SERDs dopo le cicline

HER2DX en el estudio PHERgain

Lo studio BEGONIA nelle paziento con tumore triplo negativo

HS20089 - un nuovo ADC che si affaccia sulla scenda del TNBC

Dato-DXd - nowy gracz w zaawansowanym raku luminalnym

The optimal timing of RT after radical prostatectomy and QoL data of ENZA therapy in nmHSPC

Targeted therapy will move forward - but more robust data is needed.

What is the future of immune therapy in prostate cancer?

Should we use zoledronic acid in all ADT patients?

ENZA P:Trial and controversies

Big data and AI prediction tools

EMBARK expands ENZA indication to PCa

Precision medicine at mCRCP

Embark without fear

Combination of radioligand therapy with chemotherapy useful

Early use of enzalutamide in advanced prostate cancer

Immunotherapy in metastatic PCa

PSMAfore unleashes urooncologic opportunity

Longterm toxicity of adjuvant RT after prostatectomy

RADICALS RT: Trial and controversies

IO therapy in metastatic prostate cancer.

Negative data for pembrolizumab in mHSCPC & mCRPC

PSMA FORE: Trial and controversies

Osteoprotection at mHSPC

When immunotherapy is probably not the best choice: The case of untreated metastatic prostate cancer

Brave New World in mCRPC

Lu-PSMA leads forward

STAMPEDE. Bone prediction not for everyone - better risk stratification for PCa

EMBARK - Quality of Life

CXCR2 inhibitor in PCa

Salvage radiotherapy the new standard

TITAN: ultra-low PSA = best prognosis

STAMPEDE data. Skelettstärkande och riskstratifiering.

Big Data och AI för prediktion vid prostatacancer

Immunterapi vid prostatacancer

CXCR2 hämmare och prostatacancer

EMBARK och livskvalitet

Cuando la inmunoterapia probablemente no es la mejor elección: El caso del cancer de próstata avanzado en pacientes no seleccionados

FGFR inhibitors and ADC combinations in urothelial cancer - new options for the future?!

Part 2: New standard of care in first line urothelial cancer!

Part1: New standard of care in first line urothelial cancer?!

New SoC in firstline bladder cancer

DAD, DAD-IO

Amazing new data in bladder cancer

Chemo-IO establishes itself in the first-line treatment of bladder cancer

When the history of ADC is written: Redefining first-line standard of care in mUC!

The FGFR story in bladder cancer at ESMO23

Unique bladder delivery system of gemcitabine herolds remarkable response

EV + Pembro as standard of care in first-line therapy of bladder cancer

FGFR inhibitors: What is the best scenario for this family of compounds?

Στιγμιότυπα για τον καρκίνο των νεφρών και της ουροδόχου κύστης στο ESMO23

Reescribiendo la historia de una enfermedad: Nuevo estándar de tratamiento en primera linea en cancer urotelial avanzado

Inhibidores de FGFR: Cual es el mejor escenario para esta familia de fármacos?

L'histoire du FGFR dans le cancer de la vessie à l'ESMO23

Is de-escalating therapy ready for prime-time?

Important new treatment option but only for subset of patients?

Where does the future therapy go in renal cell carcinoma?

New 3rd line therapy for RCC

Belzutifan - whats next kidney cancer?

Clearing up non-clear cell RCC

Intermittent therapy also possible with TKIs

New mode of action in mRCC - ready for prime time?

Kidney cancer highlights at ESMO23

Belzutifan in later lines of therapy

ALINA - remarkably positive DFS in early-stage ALK+ NSCLC

Moving patients to the neoadjuvant setting in non-metastatic NSCLC

Scene is set for inductive immunotherapy

Big improvements in early stage and a subset of metatstic NSCLC

Perioperative IO: OS-benefi from KEYNOTE-671

Substantial improvement in local regional NSCLC

My highlights from ESMO 2023

Adjuvant alectinib in patients with early-stage ALK+ NSCLC

Neoadjuvant chemo-immunotherapy new standards in early & advanced NSCLC

Circulating DNA in AEGEAN trial

Perioperativ immunotherapy for all resectable stage II-IIIb NSCLC patients

ALINA - immediate change of practice!

ALINA - a new paradigm in operated NSCLC with ALK-fusion

Les points forts de l'ESMO 2023

Perioperatieve chemo-immunotherapie voor alle patienten met resectabel stadium II-IIIB NSCLC?

Gros progrès dans les traitments medicaeux des stades precocers et par des sous-groupes au stade métastatique

ALINA - un nouveau paradigme dans cBNPC avec la fusion ALK

I miei punti salienti di ESMO 2023

ESMO2023-impact on everyday practice!

Rare oncogenic alterations: landmark results on exon 20 insertion & confirming data on RET fusion+ NSCLC

Activating EGFR-mutation - what's coming up?

Evolving landscape of ADCs

New standard of care for metastatic EGFR exon 20 insertion mutated NSCLC

MARIPOSA II: Trial and controversies

Amivantamab at progression? MARIPOSA-2 trial

MARIPOSA: Trial and controversies

RET-TKI: Standard in 1st line RET fusion-positive NSCLC

Amivantamab as a new SoC for EGFR Exon 20 Insertion-mutated aNSCLC

Does immunotherapy still have a place in EGFR-positive mNSCLC?

PAPILLON - bringing together therapy for the 1st line

Do ADCs have brain activity?

Substantial improvement in rare alterations

By unanimous decision and still the champion – docetaxel!

NRG fusions: a new drugable target?

Datopotamab deruxtecan - new SOC in 2nd line adv/met NSCLC?

Brain metastases – options to improve the systemic treatment

LIBRETO - a positive study, but was it necessary?

Big improvements in early stage and a subset of metatstic NSCLC

Adagrasib + pembrolizumab in patients with KRASG12C mutation

Changing treatment landscape in EGFR-mutated NSCLC

TROPION-Lung01: positive development

Treatment sequences for EGFR-mutated Patients

Practice changing results on exon 20 insertion mNSCLC

My highlights from ESMO 2023

Amivantamab upfront? MARIPOSA trial

I miei punti salienti di ESMO 2023

Veränderte Behandlungslandschaft bei EGFR-mutiertem NSCLC

Nieuwe standaard voor gemetastaseerd EGFR exon20 insertie gemuteerd NSCLC

Les points forts de l'ESMO 2023

Quelles séquences thérapeutiques pour les patients EGFR mutés

Datopotamab deruxtecan - new SOC in 2nd line adv/met NSCLC?

Amivantamab at progression? MARIPOSA-2 trial

Amivantamab upfront? MARIPOSA trial

L’amivantamab, nouveau standard de traitement pour les EGFR exon 20

Heeft immunotherapie nog een plek in de behandeling van EGFR-positief gemetastaseerd NSCLC?

Gros progrès dans les traitments medicaeux des stades precocers et par des sous-groupes au stade métastatique

Impact of T-cell engagers in SCLC

Tarlatamab in SCLC

A new option in relapsed SCLC

New hope for patients with SCLC

Neue Hoffnung für Patienten mit SCLC

Update on gynaecological cancers

Evolution of the revolution - the RUBY trial

Precision oncology in CUP

PCO Therapeutics

New data on sarkomas

First data on luveltamab in multiline treatment for endometrial cancer

New data on H&N Cancer